Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade C 1.28 4.07% 0.05
SCYX closed up 4.07 percent on Friday, May 24, 2019, on 61 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical SCYX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup 4.07%
Reversal New Lows Setup Bearish Swing Setup 4.07%
Lower Bollinger Band Walk Weakness 4.07%
Below Lower BB Weakness 4.07%
Down 3 Days in a Row Weakness 4.07%
Down 4 Days in a Row Weakness 4.07%
Lower Bollinger Band Touch Weakness 4.07%

Older signals for SCYX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Medicine Medical Specialties Pharmaceutical Drugs Medication Anti Infectives Hepatitis C Interferon Pegylation
Is SCYX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.15
52 Week Low 0.35
Average Volume 734,879
200-Day Moving Average 1.163
50-Day Moving Average 1.5712
20-Day Moving Average 1.458
10-Day Moving Average 1.377
Average True Range 0.0941
ADX 29.52
+DI 9.9749
-DI 28.2079
Chandelier Exit (Long, 3 ATRs ) 1.4677
Chandelier Exit (Short, 3 ATRs ) 1.5023
Upper Bollinger Band 1.668
Lower Bollinger Band 1.248
Percent B (%b) 0.08
BandWidth 28.806584
MACD Line -0.0798
MACD Signal Line -0.054
MACD Histogram -0.0259
Fundamentals Value
Market Cap 34.2 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.33
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.43
Resistance 3 (R3) 1.43 1.37 1.41
Resistance 2 (R2) 1.37 1.34 1.38 1.40
Resistance 1 (R1) 1.33 1.31 1.35 1.33 1.39
Pivot Point 1.27 1.27 1.29 1.28 1.27
Support 1 (S1) 1.23 1.24 1.25 1.23 1.17
Support 2 (S2) 1.17 1.21 1.18 1.16
Support 3 (S3) 1.13 1.17 1.16
Support 4 (S4) 1.13